{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T13:36:29Z","timestamp":1762349789841,"version":"build-2065373602"},"reference-count":40,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T00:00:00Z","timestamp":1762300800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceuticals"],"abstract":"<jats:p>Background\/Objectives: Cognitive impairment (CI) is a common complication of heart failure (HF) that undermines self-care, adherence, and outcomes. This systematic review assessed the cognitive effects of pharmacological HF management and related cardiovascular therapies, identifying potential risks and benefits. Methods: Following PRISMA 2020, we searched PubMed, EMBASE, and Scopus for articles published in English between 1 January 2010 and 31 January 2025 (last search 31 January 2025). We included RCTs and cohort studies in adults with HF or high cardiovascular risk that reported cognitive outcomes. Non-pharmacological interventions, studies without relevant cognitive endpoints, and non-original research were excluded. Risk of bias was assessed using RoB 2 for RCTs and the Newcastle\u2013Ottawa Scale for observational studies. Due to heterogeneity in study designs and cognitive measures, results were synthesized qualitatively without meta-analysis. Results: Of 530 records screened, 11 studies encompassing 58,190 participants met the inclusion criteria. Intensive blood pressure (BP) lowering was consistently associated with reduced risk of mild cognitive impairment or dementia compared with standard BP control. In HF populations, sacubitril\/valsartan showed no adverse cognitive effects versus other RAAS inhibitors. Across RCTs and observational studies, \u03b2-blockers, ACE inhibitors, ARBs, diuretics, and statins showed no evidence of significant cognitive impairment. Comparisons of anticoagulants (dabigatran vs. warfarin; warfarin vs. aspirin) revealed no differences in cognitive trajectories, while optimized medical therapy was associated with parallel improvements in cognitive scores, left ventricular function, and renal parameters. Limitations: Evidence remains constrained by heterogeneity in study design and cognitive assessment tools (often brief screening instruments), inconsistent reporting, and generally short follow-up durations, which may obscure subtle or long-term effects. Conclusions: Contemporary pharmacological therapies for HF appear cognitively safe. Intensive BP control may confer cognitive benefit in high-risk populations, while guideline-directed treatments show no consistent evidence of cognitive harm. Optimized medical therapy may even support cognitive improvement alongside cardiac and renal recovery. Routine cognitive assessment should be integrated into HF care to support individualized management.<\/jats:p>","DOI":"10.3390\/ph18111671","type":"journal-article","created":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T13:19:29Z","timestamp":1762348769000},"page":"1671","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Cognitive Safety and Outcomes of Pharmacological Management in Heart Failure: A Systematic Review"],"prefix":"10.3390","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-9630-9511","authenticated-orcid":false,"given":"Wiktoria","family":"Balcerzak","sequence":"first","affiliation":[{"name":"Department of Neurology, Upper-Silesian Medical Center of the Medical University of Silesia, 40-055 Katowice, Poland"},{"name":"Doctoral School of Medical and Health Sciences, Medical University of Silesia, 40-055 Katowice, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7866-3689","authenticated-orcid":false,"given":"Gabriela","family":"Poczatek","sequence":"additional","affiliation":[{"name":"Doctoral School of Medical and Health Sciences, Medical University of Silesia, 40-055 Katowice, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5081-8343","authenticated-orcid":false,"given":"Agnieszka","family":"Gorzkowska","sequence":"additional","affiliation":[{"name":"Department of Neurology, Upper-Silesian Medical Center of the Medical University of Silesia, 40-055 Katowice, Poland"},{"name":"Department of Neurology, School of Health Sciences, Medical University of Silesia, 40-055 Katowice, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3558-3608","authenticated-orcid":false,"given":"Anna","family":"Blach","sequence":"additional","affiliation":[{"name":"Department of Cardiology and Structural Heart Diseases, Medical University of Silesia, 40-055 Katowice, Poland"},{"name":"Nuclear Medicine Department, Voxel Diagnostic Center, 40-514 Katowice, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michal","family":"Jurkiewicz","sequence":"additional","affiliation":[{"name":"Students\u2019 Scientific Society, Department of Neurology, School of Health Sciences, Medical University of Silesia, 40-055 Katowice, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2481-7528","authenticated-orcid":false,"given":"Anetta","family":"Lasek-Bal","sequence":"additional","affiliation":[{"name":"Department of Neurology, Upper-Silesian Medical Center of the Medical University of Silesia, 40-055 Katowice, Poland"},{"name":"Department of Neurology, School of Health Sciences, Medical University of Silesia, 40-055 Katowice, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2025,11,5]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1038\/s41569-024-01046-6","article-title":"Global epidemiology of heart failure","volume":"21","author":"Khan","year":"2024","journal-title":"Nat. Rev. Cardiol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"ehad655.876","DOI":"10.1093\/eurheartj\/ehad655.876","article-title":"The global burden of heart failure: A systematic analysis for the Global Burden of Disease Study 2021","volume":"44","author":"Roth","year":"2023","journal-title":"Eur. Heart J."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur. Heart J."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"3627","DOI":"10.1093\/eurheartj\/ehad195","article-title":"2023 Focused Update of the 2021 ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure: Developed by the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) With the special contribution of the Heart Failure Association (HFA) of the ESC","volume":"44","author":"McDonagh","year":"2023","journal-title":"Eur. Heart J."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1161\/CIRCRESAHA.119.315813","article-title":"Brain Damage with Heart Failure: Cardiac Biomarker Alterations and Gray Matter Decline","volume":"126","author":"Mueller","year":"2020","journal-title":"Circ. Res."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"e425","DOI":"10.1161\/STR.0000000000000476","article-title":"Cardiac Contributions to Brain Health: A Scientific Statement from the American Heart Association","volume":"55","author":"Testai","year":"2024","journal-title":"Stroke"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.neuroscience.2024.12.004","article-title":"The Intricate Brain\u2013Heart Connection: The Relationship between Heart Rate Variability and Cognitive Functioning","volume":"565","author":"Forte","year":"2025","journal-title":"Neuroscience"},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Goh, F.Q., Kong, W.K.F., Wong, R.C.C., Chong, Y.F., Chew, N.W.S., Yeo, T.-C., Sharma, V.K., Poh, K.K., and Sia, C.-H. (2022). Cognitive Impairment in Heart Failure\u2014A Review. Biology, 11.","DOI":"10.3390\/biology11020179"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1002\/ehf2.15144","article-title":"Connecting the Dots: A Narrative Review of the Relationship between Heart Failure and Cognitive Impairment","volume":"12","author":"Massussi","year":"2025","journal-title":"ESC Heart Fail."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1111\/chf.12007","article-title":"Elevated Levels of Interleukin 6 and C-Reactive Protein Associated with Cognitive Impairment in Heart Failure","volume":"19","author":"Athilingam","year":"2013","journal-title":"Congest. Heart Fail."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1177\/1474515111435606","article-title":"Screening for Mild Cognitive Impairment in Patients with Heart Failure: Montreal Cognitive Assessment versus Mini Mental State Exam","volume":"12","author":"Cameron","year":"2013","journal-title":"Eur. J. Cardiovasc. Nurs."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1007\/s11065-020-09463-3","article-title":"Neuropsychological Assessment and Screening in Heart Failure: A Meta-Analysis and Systematic Review","volume":"31","author":"Connors","year":"2021","journal-title":"Neuropsychol. Rev."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"407","DOI":"10.2147\/CLEP.S44560","article-title":"Cognitive Impairment and Self-Care in Heart Failure","volume":"5","author":"Hajduk","year":"2013","journal-title":"Clin. Epidemiol."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Mapelli, D., Bardi, L., Mojoli, M., Volpe, B., Gerosa, G., Amodio, P., and Daliento, L. (2011). Neuropsychological Profile in a Large Group of Heart Transplant Candidates. PLoS ONE, 6.","DOI":"10.1371\/journal.pone.0028313"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"306","DOI":"10.5014\/ajot.2011.000588","article-title":"Executive Dysfunction and Depressive Symptoms Associated with Reduced Participation of People with Severe Congestive Heart Failure","volume":"65","author":"Foster","year":"2011","journal-title":"Am. J. Occup. Ther."},{"key":"ref_16","first-page":"106","article-title":"Cognitive Decline in Heart Failure: More Attention Is Needed","volume":"2","year":"2016","journal-title":"Card. Fail. Rev."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1111\/jocn.12214","article-title":"Executive Dysfunction Is Independently Associated with Reduced Functional Independence in Heart Failure","volume":"23","author":"Alosco","year":"2014","journal-title":"J. Clin. Nurs."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/j.cardfail.2024.01.003","article-title":"Cognitive Impairment in Heart Failure: A Heart Failure Society of America Scientific Statement","volume":"30","author":"Goyal","year":"2024","journal-title":"J. Card. Fail."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/0163-7258(90)90092-G","article-title":"Beta-Blockers and Central Nervous System Side Effects","volume":"46","author":"McAinsh","year":"1990","journal-title":"Pharmacol. Ther."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/s00424-012-1102-2","article-title":"The Brain Renin\u2013Angiotensin System: A Diversity of Functions and Implications for CNS Diseases","volume":"465","author":"Wright","year":"2013","journal-title":"Pflugers Arch."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"33","DOI":"10.9740\/mhc.2018.01.033","article-title":"Diuretics: A Possible Keystone in Upholding Cognitive Health","volume":"8","author":"DeLoach","year":"2018","journal-title":"Ment. Health Clin."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 Statement: An Updated Guideline for Reporting Systematic Reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.1161\/HYPERTENSIONAHA.124.22876","article-title":"High-Sensitivity Troponin T, NT-proBNP, and Cognitive Outcomes in SPRINT","volume":"81","author":"Haney","year":"2024","journal-title":"Hypertension"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1161\/CIRCULATIONAHA.124.068774","article-title":"Effect of Sacubitril\/Valsartan on Cognitive Function in Patients with Heart Failure with Preserved Ejection Fraction: A Prespecified Analysis of PARAGON-HF","volume":"150","author":"Dewan","year":"2024","journal-title":"Circulation"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2042","DOI":"10.1016\/j.jacc.2021.08.073","article-title":"Effect of \u03b2-Blocker Withdrawal on Functional Capacity in Heart Failure with Preserved Ejection Fraction","volume":"78","author":"Palau","year":"2021","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"e190223","DOI":"10.1001\/jamanetworkopen.2019.0223","article-title":"Assessment of Vascular Event Prevention and Cognitive Function among Older Adults with Preexisting Vascular Disease or Diabetes: A Secondary Analysis of Three Randomized Clinical Trials","volume":"2","author":"Offer","year":"2019","journal-title":"JAMA Netw. Open"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1097\/JCN.0000000000000216","article-title":"Evidence-Based Heart Failure Medications and Cognition","volume":"31","author":"Bratzke","year":"2016","journal-title":"J. Cardiovasc. Nurs."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1159\/000371509","article-title":"Effects of Pioglitazone or Exercise in Older Adults with Mild Cognitive Impairment and Insulin Resistance: A Pilot Study","volume":"5","author":"Hildreth","year":"2015","journal-title":"Dement. Geriatr. Cogn. Dis. Extra"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1002\/ehf2.12498","article-title":"Oral Modified Release Morphine for Breathlessness in Chronic Heart Failure: A Randomized Placebo-Controlled Trial","volume":"6","author":"Johnson","year":"2019","journal-title":"ESC Heart Fail."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1161\/STROKEAHA.113.004009","article-title":"Warfarin versus Aspirin for Prevention of Cognitive Decline in Atrial Fibrillation: Randomized Controlled Trial (Birmingham Atrial Fibrillation Treatment of the Aged Study)","volume":"45","author":"Mavaddat","year":"2014","journal-title":"Stroke"},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Caramelli, B., Yu, P.C., Cardozo, F.A.M., Magalh\u00e3es, I.R., Spera, R.R., Amado, D.K., Escalante-Rojas, M.C., Gualandro, D.M., Calderaro, D., and Tavares, C.A.M. (2022). Effects of Dabigatran versus Warfarin on 2-Year Cognitive Outcomes in Older Patients with Atrial Fibrillation: Results from the GIRAF Randomized Clinical Trial. BMC Med., 20.","DOI":"10.1186\/s12916-022-02563-2"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"254","DOI":"10.18413\/2658-6533-2023-9-2-0-8","article-title":"Cognitive Function of Elderly and Senile Patients on the Background of Long-Term Pharmacotherapy of Chronic Heart Failure with Low Ejection Fraction","volume":"9","author":"Osipova","year":"2023","journal-title":"Res. Results Biomed."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1007\/s00059-018-4683-5","article-title":"Cognitive Performance of Patients with Chronic Heart Failure on Sacubitril\/Valsartan","volume":"44","author":"Ariano","year":"2019","journal-title":"Herz"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"e70008","DOI":"10.1111\/eci.70008","article-title":"Impact of Heart Failure Medications on Cognitive Function: A Systematic Review","volume":"55","author":"Jahangiri","year":"2025","journal-title":"Eur. J. Clin. Investig."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.2337\/dc21-2434","article-title":"Empagliflozin Improves Cognitive Impairment in Frail Older Adults with Type 2 Diabetes and Heart Failure with Preserved Ejection Fraction","volume":"45","author":"Mone","year":"2022","journal-title":"Diabetes Care"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"e70416","DOI":"10.1002\/alz.70416","article-title":"Effects of the SGLT2 Inhibitor Dapagliflozin in Early Alzheimer\u2019s Disease: A Randomized Controlled Trial","volume":"21","author":"Burns","year":"2025","journal-title":"Alzheimer\u2019s Dement."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1016\/j.amjmed.2019.04.022","article-title":"Digoxin Use and Associated Adverse Events among Older Adults","volume":"132","author":"Angraal","year":"2019","journal-title":"Am. J. Med."},{"key":"ref_38","first-page":"CD003120","article-title":"Ginkgo biloba for Cognitive Impairment and Dementia","volume":"1","author":"Birks","year":"2009","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"14","DOI":"10.17756\/jnen.2019-047","article-title":"Citicoline in the Treatment of Cognitive Impairment","volume":"5","author":"Secades","year":"2019","journal-title":"J. Neurol. Exp. Neurosci."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"e313","DOI":"10.1016\/j.jns.2013.07.1172","article-title":"Use of Pramiracetam in Elderly Patients with Mild Cognitive Impairment and Arterial Hypertension","volume":"333","author":"Bachinskaya","year":"2013","journal-title":"J. Neurol. Sci."}],"container-title":["Pharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1424-8247\/18\/11\/1671\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T13:32:28Z","timestamp":1762349548000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1424-8247\/18\/11\/1671"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,5]]},"references-count":40,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2025,11]]}},"alternative-id":["ph18111671"],"URL":"https:\/\/doi.org\/10.3390\/ph18111671","relation":{},"ISSN":["1424-8247"],"issn-type":[{"value":"1424-8247","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,5]]}}}